Immunocore Holdings PLC
IMCR32.945USD
-0.045-0.14%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
1.65BCap. mercado
PérdidaP/E TTM
Más Datos de Immunocore Holdings PLC Compañía
Immunocore Holdings plc is a United Kingdom-based commercial-stage biotechnology company. The Company is engaged in the development of TCR bispecific immunotherapies, ImmTAX, which immunes mobilizing monoclonal TCRs Against X disease, designed to treat a range of diseases, including cancer, autoimmune and infectious disease. The Company has a clinical-stage pipeline of wholly owned and partnered programs across three different therapeutic areas: oncology, infectious diseases, and autoimmune and inflammation diseases. Its lead product, KIMMTRAK, is a TCR therapeutic for the treatment of patients with unresectable or metastatic uveal melanoma (mUM), in the United States, European Union, Canada, Australia and the United Kingdom. Its pipeline products include IMC-F106C, IMC-F115C, IMC-F119C, IMC-F117C, IMC-F113V, IMC-I109V, IMC-SII8AI, among others. Its clinical programs are being conducted with patients with a range of cancers including melanoma, lung, gastric and others.
Información de la empresa
Símbolo de cotizaciónIMCR
Nombre de la empresaImmunocore Holdings PLC
Fecha de salida a bolsaFeb 05, 2021
Director ejecutivoDr. Bahija Jallal, Ph.D.
Número de empleados493
Tipo de seguridadDepository Receipt
Fin del año fiscalFeb 05
Dirección92 Park Drive Milton Park
CiudadABINGDON
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited Kingdom
Código postalOX14 4RY
Teléfono441235438600
Sitio Webhttps://www.immunocore.com/
Símbolo de cotizaciónIMCR
Fecha de salida a bolsaFeb 05, 2021
Director ejecutivoDr. Bahija Jallal, Ph.D.
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Prof. John Bell
Prof. John Bell
Independent Chairman of the Board
Independent Chairman of the Board
13.45K
--
Mr. Roy S. Herbst, M.D., Ph.D.
Mr. Roy S. Herbst, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Clayton Robertson
Mr. Clayton Robertson
Head of Investor Relations
Head of Investor Relations
--
--
Dr. Bahija Jallal, Ph.D.
Dr. Bahija Jallal, Ph.D.
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Ms. Tina St. Leger
Ms. Tina St. Leger
Chief Human Resources Officer
Chief Human Resources Officer
--
--
Dr. William Pao, M.D., Ph.D.
Dr. William Pao, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Ranjeev Krishana
Mr. Ranjeev Krishana
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Siddharth Kaul
Mr. Siddharth Kaul
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Kristine Peterson
Ms. Kristine Peterson
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Prof. Peter Ratcliffe
Prof. Peter Ratcliffe
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Prof. John Bell
Prof. John Bell
Independent Chairman of the Board
Independent Chairman of the Board
13.45K
--
Mr. Roy S. Herbst, M.D., Ph.D.
Mr. Roy S. Herbst, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Clayton Robertson
Mr. Clayton Robertson
Head of Investor Relations
Head of Investor Relations
--
--
Dr. Bahija Jallal, Ph.D.
Dr. Bahija Jallal, Ph.D.
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Ms. Tina St. Leger
Ms. Tina St. Leger
Chief Human Resources Officer
Chief Human Resources Officer
--
--
Dr. William Pao, M.D., Ph.D.
Dr. William Pao, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Desglose de ingresos
Divisa: USDActualizado: dom., 6 de jul
Divisa: USDActualizado: dom., 6 de jul
FY2024
FY2023
FY2023Q3
FY2023Q2
FY2022
FY2022Q3
FY2022Q2
FY2020
FY2019
Sin datos
Por regiónUSD
Nombre
Ganancia
Proporción
United States
226.69M
73.08%
Europe
73.22M
23.61%
International
10.08M
3.25%
Collaboration revenue
213.00K
0.07%
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: sáb., 17 de may
Actualizado: sáb., 17 de may
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
T. Rowe Price Investment Management, Inc.
14.25%
Wellington Management Company, LLP
12.39%
RTW Investments L.P.
9.84%
Fidelity Management & Research Company LLC
9.71%
PRIMECAP Management Company
5.41%
Other
48.41%
Accionistas
Accionistas
Proporción
T. Rowe Price Investment Management, Inc.
14.25%
Wellington Management Company, LLP
12.39%
RTW Investments L.P.
9.84%
Fidelity Management & Research Company LLC
9.71%
PRIMECAP Management Company
5.41%
Other
48.41%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
41.30%
Investment Advisor/Hedge Fund
26.52%
Hedge Fund
22.94%
Corporation
5.15%
Private Equity
3.16%
Research Firm
2.66%
Pension Fund
0.42%
Bank and Trust
0.25%
Venture Capital
0.04%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
292
50.72M
102.46%
-9.05M
2025Q1
304
50.82M
102.67%
-9.36M
2024Q4
304
48.99M
99.30%
-7.33M
2024Q3
299
49.26M
99.94%
-5.38M
2024Q2
298
47.15M
96.58%
+1.62M
2024Q1
283
47.77M
97.93%
+3.51M
2023Q4
262
40.76M
86.07%
-2.70M
2023Q3
246
44.95M
95.97%
-1.86M
2023Q2
236
43.68M
94.12%
-435.38K
2023Q1
218
40.62M
88.44%
-3.40M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
T. Rowe Price Investment Management, Inc.
7.05M
14.25%
+351.61K
+5.25%
Mar 31, 2025
Wellington Management Company, LLP
6.13M
12.39%
-485.33K
-7.33%
Mar 31, 2025
RTW Investments L.P.
4.87M
9.84%
--
--
Mar 31, 2025
Fidelity Management & Research Company LLC
4.81M
9.71%
+23.88K
+0.50%
Mar 31, 2025
PRIMECAP Management Company
2.68M
5.41%
+10.10K
+0.38%
Mar 31, 2025
Eli Lilly Vostok SA Geneva
2.55M
5.15%
--
--
Mar 21, 2025
Baker Bros. Advisors LP
2.32M
4.69%
+807.34K
+53.28%
Mar 31, 2025
Tang Capital Management, LLC
1.92M
3.87%
+360.11K
+23.15%
Mar 31, 2025
T. Rowe Price Associates, Inc.
1.89M
3.81%
-299.59K
-13.70%
Mar 31, 2025
Kynam Capital Management LP
1.70M
3.43%
+470.00K
+38.35%
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 2 de ago
Actualizado: sáb., 2 de ago
Nombre
Proporción
Virtus LifeSci Biotech Products ETF
1.7%
Tema Oncology ETF
1.18%
ALPS Medical Breakthroughs ETF
1.07%
Invesco Nasdaq Biotechnology ETF
0.14%
ProShares Ultra Nasdaq Biotechnology
0.14%
SPDR S&P International Small Cap ETF
0.12%
iShares Biotechnology ETF
0.1%
iShares Intl Small Cap Equity Factor ETF
0.09%
Fidelity Nasdaq Composite Index ETF
0.01%
SPDR Portfolio Developed World ex-US ETF
0.01%
Ver más
Virtus LifeSci Biotech Products ETF
Proporción1.7%
Tema Oncology ETF
Proporción1.18%
ALPS Medical Breakthroughs ETF
Proporción1.07%
Invesco Nasdaq Biotechnology ETF
Proporción0.14%
ProShares Ultra Nasdaq Biotechnology
Proporción0.14%
SPDR S&P International Small Cap ETF
Proporción0.12%
iShares Biotechnology ETF
Proporción0.1%
iShares Intl Small Cap Equity Factor ETF
Proporción0.09%
Fidelity Nasdaq Composite Index ETF
Proporción0.01%
SPDR Portfolio Developed World ex-US ETF
Proporción0.01%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
